Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,...
Reexamination Certificate
1996-01-02
2003-08-26
Kunz, Gary (Department: 1647)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
C514S002600, C514S012200, C530S350000, C530S399000
Reexamination Certificate
active
06610296
ABSTRACT:
FIELD OF THE INVENTION
This application relates to the production of polypeptides involved in neuronal survival and/or growth and in angiogenesis, in particular the production of purified forms thereof by means of recombinant DNA technology.
BACKGROUND OF THE INVENTION
A number of protein neurotrophic factors, or neurotrophins, have been identified which influence growth and development of the vertebrate nervous system. It is believed that these factors play an important role in promoting the differentiation, survival, and function of diverse groups of neurons in the brain and periphery.
The belief that neurotrophic factors have important signalling functions in neural tissues is based upon the precedent established by work with nerve growth factor (NGF). NGF has been shown, both in vitro and in vivo, to support the survival of sympathetic, sensory, and basal forebrain neurons. Administration of exogenous NGF rescues neurons from cell death during development. Conversely, removal or sequestration of endogenous NGF by administration of anti-NGF antibodies promotes such cell death. Heumann,
J. Exp. Biol.
132:133-150 (1987); Hefti,
J. Neurosci.
6:2155-2162 (1986); Thoenen and Barde,
Annu. Rev. Physiol.
60:284-335 (1980).
Additional neurotrophic factors related to NGF have since been identified. These include brain-derived neurotrophic factor (BDNF) (Leibrock, et al.,
Nature
341:149-152 (1989)), neurotrophin-3 (NT-3) (Kaisho, et al.,
FEBS Lett.
266:187 (1990); Maisonpierre, et al.,
Science
247:1446 (1990); Rosenthal, et al.,
Neuron
4:767 (1990)), and neurotrophin 4/5 (NT-4/5) (Berkmeier, et al.,
Neuron
7:857-866 (1991)).
Neurotrophins, similar to other polypeptide growth factors, affect their target cells through interactions with cell surface receptors. According to our current understanding, two kinds of transmembrane glycoproteins act as receptors for the known neurotrophins. Equilibrium binding studies have shown that neurotrophin-responsive neuronal cells possess a common low molecular weight (65,000-80,000 Daltons), low affinity receptor, typically referred to as p75
LNGFR
or p75, and high molecular weight (130,000-150,000 Daltons), high and low affinity receptors that are members of the trk family of receptor tyrosine kinases.
Receptor tyrosine kinases are known to serve as receptors for a variety of protein factors that promote cellular proliferation, differentiation, and survival. In addition to the trk receptors, examples of other receptor tyrosine kinases include the receptors for epidermal growth factor (EGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF). Typically, these receptors span the cell membrane, with one portion of the receptor being intracellular and in contact with the cytoplasm, and another portion of the receptor being extracellular. Binding of a ligand to the extracellular portion of the receptor is believed to induce tyrosine kinase activity in the intracellular portion of the receptor, with ensuing phosphorylation of various intracellular proteins involved in cellular signalling pathways.
In addition to receptor tyrosine kinases that serve as receptors for known protein factors, many receptor-like tyrosine kinases have been identified for which no ligand is known. Examples of such “orphan” receptors include recently discovered members of the eph family, which includes eph, elk, cek5, cek7, mek4/cek4/hek, sek, hek2, and bsk (Tuzi, et al., Br. J. Cancer 69:417-421 (1994); Zhou, et al., J. Neurosci. Res. 37:129-143 (1994)). Recently, other eph family receptor ligands have been reported including B61, an Eck receptor ligand (Bartley, et al,
Nature
368:558-560 (1994) and Pandey et al.
Science
(1995) 268:567-569), ELF-1, a Mek4 and Sek receptor ligand (Cheng et al. Cell (1995) 82:371-381), Ehk-1-2, LERK2, HTK-L and CEK5-L. After the discovery reported in the present application was made, a chicken AL-1 homolog termed RAGS was reported (Drescher et al.
Cell
(1995) 82:359-370).
Although eph family members are expressed in many different tissues, several family members are expressed in the nervous system or specifically in neurons (Maisonpierre, et al., Oncogene 8:3277-3288 (1993); Lai, et al., Neuron 6:691-704 (1991). In order to better understand the role of these and other orphan receptor tyrosine kinases in the nervous system, it would be useful to identify new ligands that bind to such receptors.
The present invention is based on successful research resulting in the identification, cloning, and sequencing of an eph-related tyrosine kinase receptor, referred to as REK7, and its ligand, referred to as AL-1.
It is an object of the present invention to provide nucleic acid encoding AL-1, and to use the nucleic acid to produce AL-1 in recombinant host cells for diagnostic use or for therapeutic use.
It is another object to use such nucleic acids encoding AL-1, and portions thereof, to identify related nucleic acids in the cells or tissues of various animal species.
It is another object to provide derivatives and modified forms of AL-1, including amino acid sequence variants and covalent derivatives thereof, as well as antagonists of AL-1. It is another object to prepare immunogens for raising antibodies, as well as to obtain antibodies, capable of binding to AL-1, or derivatives or modified forms thereof.
These and other objects of the invention will be apparent to the ordinary artisan upon consideration of the specification as a whole.
SUMMARY OF THE INVENTION
These objects are accomplished by first providing isolated DNA comprising the nucleotide coding sequence for AL-1, an expression vector comprising the nucleotide coding sequence for AL-1, host cells transformed with the vector, including mammalian and bacterial host cells, and a method of using a nucleic acid molecule encoding AL-1 to effect the production of AL-1, comprising culturing a host cell transfected to express such nucleic acid molecule and recovering AL-1 from the host cell culture. In this method, preferably the host cell is transfected with an expression vector comprising the nucleotide coding sequence for AL-1.
By providing the full nucleotide coding sequence for AL-1, the invention enables the production of AL-1 by means of recombinant DNA technology, thereby making available for the first time sufficient quantities of substantially pure AL-1 protein or AL-1 antagonists for diagnostic and therapeutic uses with a variety of neurological disorders and with diseases and conditions that are angiogenesis-dependent such as solid tumors, diabetic retinopathy, rheumatoid arthritis, and wound healing.
In a preferred embodiment, the invention provides AL-1 that is free of other human proteins.
Modified and variant forms of AL-1 are produced in vitro by means of chemical or enzymatic treatment or in vivo by means of recombinant DNA technology. Such polypeptides differ from native AL-1, for example, by virtue of one or more amino acid substitutions, deletions or insertions, or in the extent or pattern of glycosylation, but substantially retain a biological activity of native AL-1.
Antibodies to AL-1 are produced by immunizing an animal with AL-1 or a fragment thereof, optionally in conjunction with an immunogenic polypeptide, and thereafter recovering antibodies from the serum of the immunized animals. Alternatively, monoclonal antibodies are prepared from cells of the immunized animal in conventional fashion. Antibodies obtained by routine screening will bind to AL-1 but will not substantially bind to (i.e., cross react with) NGF, BDNF, NT-3, NT-4/5, or other neurotrophic factors. Immobilized anti-AL-1 antibodies are particularly useful in the detection of AL-1 in clinical samples for diagnostic purposes, and in the purification of AL-1.
AL-1, its derivatives, or its antibodies are formulated with physiologically acceptable carriers, especially for therapeutic use. Such carriers are used, for example, to provide sustained-release formulations of AL-1.
In further aspects, the invention provides a method for determining the presence of a nucleic acid
Caras Ingrid W.
Winslow John W.
Agarwal Atulya R.
Dreger Ginger R.
Genentech Inc.
Gucker Stephen
Heller Ehrman White & McAuliffe LLP
LandOfFree
Methods of enhancing cognitive function using an AL-1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of enhancing cognitive function using an AL-1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of enhancing cognitive function using an AL-1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3114194